TUSSIONEX PENNKINETIC
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TUSSIONEX PENNKINETIC is an extended-release oral suspension combining hydrocodone (opioid antitussive) and chlorpheniramine (antihistamine) for cough suppression. Hydrocodone acts directly on the cough center while chlorpheniramine reduces respiratory mucosa edema through H1 receptor antagonism. The Pennkinetic delivery system provides controlled release, with hydrocodone peaking at 3.4 hours and chlorpheniramine at 6.3 hours, versus 1.5 and 2.8 hours respectively for immediate-release formulations.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect declining team investment and potential portfolio deprioritization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TUSSIONEX PENNKINETIC offers limited career growth due to LOE approach and zero linked job openings; roles focus on defending market share and managing regulatory/compliance issues rather than innovation. Professionals should expect a sunset phase requiring operational excellence and cost management rather than expansion opportunities.
Brand ManagerField Sales Representative
Worked on TUSSIONEX PENNKINETIC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.